An ongoing clinical trial in the Netherlands is administering TCR modified T-cells as a treatment for patients having melanoma (including UM) or head and neck cancers that express MAGE-C2 (melanoma-associated antigen C2) (clinicaltrialsregister.eu; EudraCT#: 2019-000657-31). This evidence concerns the gene MAGEC2 and melanoma.